

GENTA INC DE/  
Form 8-K  
July 02, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **June 26, 2007**

**GENTA INCORPORATED**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-19635**

(Commission File Number)

**33-0326866**

(IRS Employer Identification No.)

**200 Connell Drive  
Berkeley Heights, NJ**

(Address of Principal Executive Offices)

**07922**

(Zip Code)

**(908) 286-9800**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- o Pre -commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

Genta Incorporated has filed an amendment to its previously submitted Complaint and Request for Correction pursuant to the U.S. Federal Data Quality Act. The complaint requests correction of the public record and retraction from the website of the U.S. Food and Drug Administration of flawed analyses and simulations of the Company's data that were filed pursuant to a New Drug Application for the use of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. The amendment has been posted at the website of the U.S. Department of Health and Human Services and can be accessed at:

<http://aspe.hhs.gov/infoquality/request&response/FDQA%20Amendment.pdf>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENTA INCORPORATED

Date: July 2, 2007

By: /s/ RICHARD J. MORAN

Name: Richard J. Moran

Title: Senior Vice President, Chief Financial  
Officer and Corporate Secretary